Skip to main content
Journal cover image

Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.

Publication ,  Journal Article
Ormseth, MJ; Yancey, PG; Solus, JF; Bridges, SL; Curtis, JR; Linton, MF; Fazio, S; Davies, SS; Roberts, LJ; Vickers, KC; Kon, V ...
Published in: Arthritis Rheumatol
September 2016

OBJECTIVE: Patients with rheumatoid arthritis (RA) have an increased risk of coronary heart disease (CHD). Some RA therapies may modify this risk, but the underlying mechanisms are unclear. The cholesterol efflux capacity of high-density lipoprotein (HDL) is associated with a reduced CHD risk in non-RA populations; however, inflammation may impair the function of HDL. The aim of this study was to evaluate whether reduced inflammation resulting from treatment with methotrexate (MTX), adalimumab (ADA), or tocilizumab (TCZ) would increase the net cholesterol efflux capacity of HDL in patients with RA. METHODS: A longitudinal multicenter study repository (Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository) provided clinical information for and serum samples from 70 patients with RA before and 6 months after starting treatment with a new drug (MTX [n = 23], ADA [n = 22], or TCZ [n = 25]). Disease activity was measured using the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR). The net cholesterol efflux capacity was measured in paired serum samples using THP-1 macrophages, and total cellular cholesterol was measured by fluorometric assay. RESULTS: The DAS28-ESR decreased with all treatments (P < 0.001). Net cholesterol efflux capacity was not significantly changed after 6 months of new RA therapy (mean ± SD 36.9 ± 17.3% units at baseline versus 38.0% ± 16.9% units at 6 months [P = 0.58]). However, change in net cholesterol efflux capacity was associated with change in the DAS28-ESR (ρ = -0.25, P = 0.04). In a post hoc analysis of patients with impaired net cholesterol efflux capacity at baseline, treatment with TCZ resulted in significant improvement in net cholesterol efflux capacity (21.9 ± 14.7% units at baseline versus 31.3% ± 12.8% units at 6 months [P < 0.02]), but this was not observed with MTX or ADA. CONCLUSION: Net cholesterol efflux capacity of HDL cholesterol did not change significantly after 6 months of new RA therapy, except in patients with impaired baseline cholesterol efflux capacity who were receiving TCZ. Change in disease activity was associated with change in the net cholesterol efflux capacity.

Duke Scholars

Published In

Arthritis Rheumatol

DOI

EISSN

2326-5205

Publication Date

September 2016

Volume

68

Issue

9

Start / End Page

2099 / 2105

Location

United States

Related Subject Headings

  • Serum
  • Middle Aged
  • Methotrexate
  • Male
  • Longitudinal Studies
  • Lipoproteins, HDL
  • Humans
  • Female
  • Cholesterol
  • Blood Sedimentation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ormseth, M. J., Yancey, P. G., Solus, J. F., Bridges, S. L., Curtis, J. R., Linton, M. F., … TETRAD Investigators, . (2016). Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. Arthritis Rheumatol, 68(9), 2099–2105. https://doi.org/10.1002/art.39675
Ormseth, Michelle J., Patricia G. Yancey, Joseph F. Solus, S Louis Bridges, Jeffrey R. Curtis, MacRae F. Linton, Sergio Fazio, et al. “Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.Arthritis Rheumatol 68, no. 9 (September 2016): 2099–2105. https://doi.org/10.1002/art.39675.
Ormseth MJ, Yancey PG, Solus JF, Bridges SL, Curtis JR, Linton MF, et al. Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2099–105.
Ormseth, Michelle J., et al. “Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.Arthritis Rheumatol, vol. 68, no. 9, Sept. 2016, pp. 2099–105. Pubmed, doi:10.1002/art.39675.
Ormseth MJ, Yancey PG, Solus JF, Bridges SL, Curtis JR, Linton MF, Fazio S, Davies SS, Roberts LJ, Vickers KC, Kon V, Michael Stein C, TETRAD Investigators. Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2099–2105.
Journal cover image

Published In

Arthritis Rheumatol

DOI

EISSN

2326-5205

Publication Date

September 2016

Volume

68

Issue

9

Start / End Page

2099 / 2105

Location

United States

Related Subject Headings

  • Serum
  • Middle Aged
  • Methotrexate
  • Male
  • Longitudinal Studies
  • Lipoproteins, HDL
  • Humans
  • Female
  • Cholesterol
  • Blood Sedimentation